NASDAQ-listed company Prenetics announced that it has reached a final agreement to transfer its ownership in ACT Genomics Holdings Company Limited to Delta Electronics, Inc. for approximately 71.78 million USD. The divestiture of ACT Genomics significantly enhances Prenetics' financial foundation, with expected cash reserves of about 86 million USD and anticipated cash and short-term assets of 117 million USD. The company maintains a zero-debt balance sheet, allowing it to explore other financial management options, including digital asset adoption and Bitcoin financial strategies.